Updates

SciTech Development Presentation - New York City Spring 2020 Oncology Investor Conference (NYCOIC). SciTech Development's corporate presentation at the New York City Spring 2020 Oncology Investor Conference March 31 - April 1, 2020. Presenting SciTech’s proprietary ST-001 nanoFenretinide technolo...

Read More
Learn more

SciTech Development will deliver a corporate presentation and meet with investors at the NYC Spring Oncology Investor Conference 2020 (3/31-4/1). Presenting SciTech’s proprietary ST-001 nanoFenretinide technology at the conference will be Earle Holsapple and Dr. Brian Leyland-Jones. Investors and...

Read More
Learn more

ST-001 nanoFenretinide T-cell lymphoma clinical trial will be initiated at Rush University Medical Center (RUMC); IRB application currently being processed/reviewed at RUMC for targeting Phase I patient treatments in July 2020. SciTech discussing participation of additional clinical sites. For ST...

Read More
Learn more

SciTech Development's patented lead drug ST-001 nanoFenretinide strategic & clinical development plan in place for clinical trial study in T-cell non-Hodgkin's lymphoma (NHL) treatment. For ST-001 nanoFenretinide investment and partnering opportunities contact Lou Scarmoutzos | (617) 283-2182 | l...

Read More
Learn more

SciTech Development's optimized and expedited clinical trials plan potentially leading to ST-001 nanoFenretinide new drug approval in 2-3 years. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

Learn more

SciTech Development Lead Drug ST-001 nanoFenretinide: Strong Intellectual Property (IP), patent expiration February 6, 2030; Orphan Drug Designated; FDA Accepted IND. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopm...

Read More
Learn more

Breaking News: The U.S. Food and Drug Administration (FDA) has accepted SciTech Development’s Investigational New Drug (IND) Application for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). For ST-001 nanoFenretinide investment and partnering opportunities contact Earle H...

Read More
Learn more

Lead drug ST-001 nanoFenretinide

A clinical stage, biopharmaceutical company that has developed a proprietary nanoparticle drug delivery system (SciTech Drug Delivery Vehicle - SDV) that enables intravenous (IV) delivery of water-insoluble (or hydrophobic) drugs. Fenretinide, SciTech's lead API (active pharmaceutical ingredient), has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity; however, its poor bioavailability (water insolubility) has impeded its development as a drug.  The patented combination of SciTech's new SDV and the fenretinide API has led to the company's lead drug candidate ST-001 nanoFenretinide with enhanced bioavailability (water solubilized) for the treatment of non-Hodgkin’s T-cell lymphoma (NHL). SciTech is actively seeking funding and strategic partnerships to conduct a Phase 1A & 1B clinical trial to reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide formulation while also confirming a newly identified immune MOA (mechanism of action) as a further goal of the protocol.  

The FDA has recently accepted SciTech’s Investigational New Drug (IND) Application for ST-001 nanoFenretinide treatment of NHL. The FDA has designated ST-001 nanoFenretinide Orphan Drug Status. For investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | eth@scitechdevelopment.com 

Contact Us

Contact

Call now
  • (313) 938-5517

Address

Get directions
281 Kercheval Avenue
Grosse Pointe Farms, MI 48236
United States

Business Hours

Mon:7:00 AM – 9:00 PM
Tue:7:00 AM – 9:00 PM
Wed:7:00 AM – 9:00 PM
Thu:7:00 AM – 9:00 PM
Fri:7:00 AM – 9:00 PM
Sat:7:00 AM – 9:00 PM
Sun:7:00 AM – 9:00 PM
Contact Us
Message sent. We'll get back to you soon.